AC
YDESW

Aristeia Capital’s YD Bio Ltd Warrants YDESW Stock Holding History

Aristeia Capital’s Portfolio YDESW Stock Details YDESW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6K Hold
63,274
– – ﹤0.01% 745
2026
Q1 		$37K Buy
63,274
+50,000
+377% +$42.5K ﹤0.01% 613
2025
Q4 		$13.6K Hold
13,274
– – ﹤0.01% 571
2025
Q3 		$27.5K Buy
+13,274
New +$23.2K ﹤0.01% 487

Other funds holding YDESW

CCMW
Cypress Capital Management (Wyoming) Sheridan, Wyoming $120M AUM 63.01% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return
Cerity Partners
Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return
TNA
True North Advisors Dallas, Texas $1.05B AUM 22.99% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

Aristeia Capital's YDESW Position: Q2 2026 in Review

Aristeia Capital held its YD Bio Ltd Warrants (YDESW) position steady in Q2 2026 at 63,274 shares worth $16.6K. The position accounts for ﹤0.01% of the portfolio, ranked #745.

Aristeia Capital first reported a position in YDESW in Q3 2025 and has held it in 4 quarters since. The position peaked at $37K in Q1 2026. 8 funds tracked by Wall St. Rank hold YDESW as of Q2 2026.

  • Aristeia Capital held 63,274 shares of YD Bio Ltd Warrants worth $16.6K as of Q2 2026.
  • Aristeia Capital left its YD Bio Ltd Warrants share count unchanged in Q2 2026.
  • YD Bio Ltd Warrants made up ﹤0.01% of Aristeia Capital's portfolio in Q2 2026, its #745 holding.
  • Aristeia Capital first reported a position in YD Bio Ltd Warrants in Q3 2025 and has held it in 4 quarters since.
  • Aristeia Capital's YD Bio Ltd Warrants position peaked at $37K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held YD Bio Ltd Warrants as of Q2 2026.

Based on Aristeia Capital's 13F filing for Q2 2026, filed 14 Aug 2026.